- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02482948
MEDIHONEY® Gel Versus Collagenase for Wound Debridement
"Prospective, Randomized, Multi-Center, Efficacy Non-inferiority Study of MEDIHONEY® Gel Versus Collagenase for Wound Debridement"
Study Overview
Status
Intervention / Treatment
Detailed Description
BACKGROUND
An important aspect of wound bed preparation for healing or grafting is the recognition that wounds often have underlying pathogenic abnormalities that cause necrotic tissue to accumulate. Therefore, in order to facilitate wound progression, repeated removal of necrotic tissue may be necessary as long as the wound is chronic. Debridement is defined as the removal of nonviable material, foreign bodies, and poorly healing tissue from a wound. Although surgeons recognize the importance of debridement, few data have been generated in randomized trials to support its use. Traditionally, debridement has been undertaken as a single therapeutic step within defined time frames. The most direct form of debridement is surgical excision. Although this may be applicable for acute wounds, it is unlikely to remove the necrotic burden that may continually accumulate in a chronic wound. Although there are other forms of debridement including enzymatic and biologic; in the case of non-healing wounds, the form of debridement with the most compelling evidence of healing efficacy is autolytic debridement , Therefore, for patients who are poor candidates for surgical debridement or have limited access to a surgeon, autolytic debridement may be considered an effective form of continuous debridement.
2.1 Primary Objective
The primary objective of this study is to evaluate the non-inferiority of MEDIHONEY® Gel (Active Leptospermum Honey-ALH Gel) compared to (Santyl) Collagenase, two FDA cleared/approved treatments, with respect to the percent reduction of necrotic (including slough and eschar) tissue in the wound at the end of 14 days +/- 2 days.
2.2 Secondary Objective
The secondary objective of this study is to compare the two treatment groups with respect to the percent reduction from randomization for necrotic tissue (including slough and eschar) at weeks 1, 3 and 4 +/- 2 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33614
- Innovative Healing Systems
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A signed and dated informed consent has been obtained from the subject.
- Subject is able and willing to comply with study procedures.
- Subject is able to comply with weekly visits.
- Subject is 18 years of age or older.
- There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of > 1cm2 to < 64cm2.
- Subject will not have currently used parenteral or oral antibiotics except for UTI.
- Diabetic subjects: HbA1c < 12.0 % within 90 days preceding enrollment.
- Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment.
- Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed.
- Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory.
- Subject with a venous ulcer must be currently receiving and using compression therapy that can be managed daily.
- Subject and caregiver are trainable and able to perform dressing changes.
- Subject has no allergies to collagenase or honey.
- Subject has no allergies to semi-occlusive or absorptive secondary dressing.
- If subject has multiple wounds only the wound that fits the inclusion criteria will be selected. If more than one wound meets criteria then the largest wound will be selected.
Exclusion Criteria:
- Steroid use >5mg daily.
- Subject is unable to cooperate with offloading and/or compression recommendations.
- ABI = or >0.8 if the wound is located on a lower extremity.
- Wound has the presence of callus requiring sharp or surgical debridement within 3 days prior to randomization and/or needs debridement using any method other than the study agent throughout study treatment.
- Subject has medical instability as deemed by the investigator.
- Subject is pregnant.
- Subject has participated in another clinical trial or wound dressing evaluation in the 30 days prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Collagenase
This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
|
Study agent to be applied daily to the wound.
Other Names:
|
Active Comparator: Active leptospermum honey
This is an active medicinal grade honey used to promote autolytic debridement and applied daily
|
STudy agent to be applied to the wound daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Necrotic tissue reduction
Time Frame: two weeks
|
Necrotic tissue percent reduction in the wound at the end of 14 days
|
two weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent wound reduction
Time Frame: 4 weeks
|
Percent wound reduction from randomization at weeks 1, 3 and 4.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ravi Patel, MD, Innovative Healing Systems
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Derma-MH001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
Groupe Hospitalier Paris Saint JosephCompletedUlcer, Leg | Ulcer AlgicFrance
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Paul EdwardsCompletedDecubitis UlcerUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingVenous Ulcer | Diabetic Ulcer | Sickle Cell Ulcer | Post-partum Women | Mixed UlcerFrance
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
AstraZenecaCompletedGastric Ulcer | Duodenal UlcerUnited States, Bulgaria, Czech Republic, Korea, Republic of, Russian Federation, South Africa, Philippines, Poland, Romania, Finland, Norway, Canada, Mexico, Argentina, Australia, Germany, Portugal, Slovakia, Thailand, Indonesia
-
Smith & Nephew, Inc.TerminatedSurgical Incision | Pressure Ulcer | Ulcer Foot | Wound Dehiscence | Ulcer, Leg | Ulcer VenousUnited Kingdom, Germany
-
Skilled Skin S.L.CompletedSurgical Wound | Diabetic Foot Ulcer | Skin Lesion | Pressure Ulcer | Hematoma | Venous Ulcer | Ischemic Ulcer | Arterial Ulcer | Diabetic Neuropathic Ulcer | Traumatic Ulcer | Ulcer, SkinSpain
Clinical Trials on Collagenase
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
Azidus BrasilSuspended
-
Stony Brook UniversityWithdrawnAdhesive Capsulitis | Frozen ShoulderUnited States
-
HealthpointCompleted
-
State University of New YorkCompletedDupuytren's Contracture
-
State University of New YorkCompletedDupuytren's ContractureUnited States
-
Sheba Medical CenterUnknown
-
Endo PharmaceuticalsCompletedEdematous SkinUnited States
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
National Taiwan University HospitalUnknownAlkaline Chemical Burn Of Cornea And Conjunctival Sac | Acid Chemical Burn Of Cornea And Conjunctival Sac | Benign Mucous Membrane Pemphigoid With Ocular InvolvementTaiwan